We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+19.05%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.5B
AUM Growth
–
Cap. Flow
+$198M
Cap. Flow %
13.22%
Top 10 Hldgs %
43.16%
Holding
169
New
166
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$31.5M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$16.3M
3
ABBV icon
AbbVie
ABBV
+$15.6M
4
ZTS icon
Zoetis
ZTS
+$14.9M
5
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$12.2M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 10.7%
2 Energy 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
CALL
Vertex Pharmaceuticals
VRTX
$123B
$184M 12.3%
+23,065
New +$1.7M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$72M 4.81%
+4,500
New +$725K
MRK icon
3
CALL
Merck
MRK
$322B
$61.5M 4.11%
+13,881
New +$620K
CELG
4
CALL
DELISTED
Celgene Corp
CELG
$55.8M 3.72%
+9,544
New +$574K
LLY icon
5
CALL
Eli Lilly
LLY
$1.08T
$50.3M 3.36%
+10,238
New +$557K
IWM icon
6
PUT
iShares Russell 2000 ETF
IWM
$79.1B
$48.6M 3.24%
+5,000
New +$478K
REGN icon
7
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
$48.1M 3.21%
+2,137
New +$498K
ACAD icon
8
CALL
Acadia Pharmaceuticals
ACAD
$4.51B
$45.7M 3.05%
+25,182
New +$347K
VRTX icon
9
PUT
Vertex Pharmaceuticals
VRTX
$123B
$42M 2.8%
+5,257
New +$387K
GILD icon
10
PUT
Gilead Sciences
GILD
$165B
$38.6M 2.57%
+7,530
New +$392K
ABBV icon
11
PUT
AbbVie
ABBV
$465B
$38.3M 2.55%
+9,253
New +$405K
AEGR
12
DELISTED
Aegerion Pharmaceuticals
AEGR
$37.6M 2.51%
+593,862
New +$31.5M
CYBX
13
PUT
DELISTED
CYBERONICS INC
CYBX
$30.9M 2.06%
+5,949
New +$282K
AGN
14
CALL
DELISTED
Allergan Inc
AGN
$30.3M 2.02%
+3,599
New +$373K
PRGO icon
15
CALL
Perrigo
PRGO
$1.44B
$27.1M 1.81%
+2,240
New +$266K
MNKD icon
16
CALL
MannKind Corp
MNKD
$1.19B
$25.2M 1.68%
+7,760
New +$208K
AZN icon
17
CALL
AstraZeneca
AZN
$269B
$22.8M 1.52%
+4,829
New +$246K
OEF icon
18
PUT
iShares S&P 100 ETF
OEF
$19.5B
$22.1M 1.47%
+2,000
New +$145K
ONXX
19
CALL
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
$21.5M 1.43%
+2,470
New +$227K
SRPT icon
20
PUT
Sarepta Therapeutics
SRPT
$1.64B
$20.8M 1.39%
+5,471
New +$196K
SRPT icon
21
Sarepta Therapeutics
SRPT
$1.64B
$17.3M 1.16%
+454,899
New +$16.3M
ZTS icon
22
PUT
Zoetis
ZTS
$32.7B
$17M 1.13%
+5,491
New +$178K
BAX icon
23
CALL
Baxter International
BAX
$12.8B
$16.9M 1.13%
+4,494
New +$172K
AEGR
24
PUT
DELISTED
Aegerion Pharmaceuticals
AEGR
$15M 1%
+2,370
New +$126K
ABBV icon
25
AbbVie
ABBV
$465B
$14.7M 0.98%
+355,626
New +$15.6M
1
2 3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Sabby Management, which disclosed 169 positions worth $1.5B. Its ten largest holdings account for 43% of the portfolio.

Its largest position is Aegerion Pharmaceuticals: 593,862 shares worth $37.6M.

By sector, the portfolio is most concentrated in Healthcare at 11% of assets, followed by Energy.

  • Sabby Management's largest Q2 2013 buy was Aegerion Pharmaceuticals: 593,862 shares worth $37.6M.
  • Sabby Management's ten largest holdings make up 43% of its $1.5B portfolio in Q2 2013.
  • Sabby Management disclosed 169 positions in Q2 2013, its first 13F filing on record.

Based on Sabby Management's 13F filing for Q2 2013, filed 14 Aug 2013.